SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ANAB reported fiscal first quarter ended September 30, 2026 results. The stock moved -3.2% on the print.
ANABearnings

Earnings reactions, page 3

AnaptysBio, Inc. (ANAB) Q1 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Collaboration revenue was $30.3 million for the three months ended September 30, 2026, compared to $76.3 million for the three months ended September 30, 2025.
  • Net income from continuing operations was $3.9 million for the three months ended September 30, 2026, compared to $56.3 million for the three months ended September 30, 2025.
  • General and administrative expenses from continuing operations were $11.6 million for the three months ended September 30, 2026, compared to $1.1 million for the three months ended September 30, 2025.
  • Research and development expenses from continuing operations were a negative $1.3 million for the three months ended September 30, 2026, compared to a negative $2.0 million for the three months ended September 30, 2025.
  • Cash, cash equivalents and investments totaled $153.0 million as of September 30, 2026.

Guidance

  • Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak monotherapy sales guidance of >$2.7 billion.
  • Anaptys anticipates paydown of the remaining ~$270 million non-recourse debt monetization in calendar H2 2027.

Notes

The separation of AnaptysBio and First Tracks Biotherapeutics was completed on April 20, 2026; beginning in the second quarter of 2026, AnaptysBio reclassified historical First Tracks Biotherapeutics, Inc. related assets, liabilities and expenses as discontinued operations.

Price and volatility reaction

The stock moved -3.2% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release47.772026-11-12
Close after release46.252026-11-13
Realised move-3.2%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →